Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adavosertib + cisplatin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Adavosertib + cisplatin is a combination therapy consisting of adavosertib, a selective Wee1 kinase inhibitor, and cisplatin, a platinum-based chemotherapeutic agent. Adavosertib prevents cells from arresting in G2 phase, forcing them to enter mitosis with unrepaired DNA damage, which enhances the cytotoxic effects of DNA-damaging agents like cisplatin. This combination has been studied primarily in head and neck squamous cell carcinoma and other advanced solid tumors.
02
Targets
WEE1 (WEE1 G2 checkpoint kinase)DNA
Beyond the preview
Go deeper on adavosertib + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adavosertib + cisplatin.